A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor. 2011

Nai-Dong Xing, and Sen-Tai Ding, and Ryoichi Saito, and Koji Nishizawa, and Takashi Kobayashi, and Takahiro Inoue, and Shinya Oishi, and Nobutaka Fujii, and Jia-Jv Lv, and Osamu Ogawa, and Hiroyuki Nishiyama
Department of Urology, Kyoto University, Graduate School of Medicine, Kyoto 606-8507, Japan.

Docetaxel-based combination chemotherapy remains the predominant treatment for castration-resistant prostate cancer. However, taxane-related drug resistance and neurotoxicity have prompted us to develop substitute treatment strategies. Eg5 (kinesin spindle protein), which is crucial for bipolar spindle formation and duplicated chromosome separation during the early phase of mitosis, has emerged as an attractive target for cancer chemotherapy. The aim of this study was to investigate the anticancer efficacy of S-(methoxytrityl)-L-cysteine (S(MeO)TLC), a novel Eg5 inhibitor in prostate cancer. Eg5 expression was examined in human prostate cancer cell lines and tissue microarrays were constructed from clinical specimens. Antiproliferative activity of S(MeO)TLC in prostate cancer cells was assessed by a cell viability assay. The anticancer effect and inhibitory mechanism of S(MeO)TLC in prostate cancer cells was further explored by Hoechst staining, flow cytometry and immunofluorescence. In addition, the antitumor effect of S(MeO)TLC on subcutaneous xenograft models was assessed. Eg5 expression was identified in PC3, DU145 and LNCaP cells. More than half of prostate cancer clinical specimens displayed Eg5 expression. S(MeO)TLC exhibited more powerful anticancer activity in prostate cancer cells compared with the other four Eg5 inhibitors tested. S(MeO)TLC induced cell death after arresting dividing cells at mitosis with distinct monopolar spindle formation. S(MeO)TLC exhibited its significant inhibitory activity (P<0.05) on subcutaneous xenograft models also through induction of mitotic arrest. We conclude that Eg5 is a good target for prostate cancer chemotherapy, and S(MeO)TLC is a potent promising anticancer agent in prostate cancer.

UI MeSH Term Description Entries
D008297 Male Males
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003545 Cysteine A thiol-containing non-essential amino acid that is oxidized to form CYSTINE. Cysteine Hydrochloride,Half-Cystine,L-Cysteine,Zinc Cysteinate,Half Cystine,L Cysteine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077143 Docetaxel A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER. Docetaxel Anhydrous,Docetaxel Hydrate,Docetaxel Trihydrate,Docetaxol,N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol,NSC 628503,RP 56976,RP-56976,Taxoltere Metro,Taxotere,N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol,RP56976
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D014320 Trityl Compounds Derivatives of triphenylmethane. Triphenylmethyl Compounds,Compounds, Triphenylmethyl,Compounds, Trityl

Related Publications

Nai-Dong Xing, and Sen-Tai Ding, and Ryoichi Saito, and Koji Nishizawa, and Takashi Kobayashi, and Takahiro Inoue, and Shinya Oishi, and Nobutaka Fujii, and Jia-Jv Lv, and Osamu Ogawa, and Hiroyuki Nishiyama
July 2018, Oncology letters,
Nai-Dong Xing, and Sen-Tai Ding, and Ryoichi Saito, and Koji Nishizawa, and Takashi Kobayashi, and Takahiro Inoue, and Shinya Oishi, and Nobutaka Fujii, and Jia-Jv Lv, and Osamu Ogawa, and Hiroyuki Nishiyama
September 2010, The Journal of urology,
Nai-Dong Xing, and Sen-Tai Ding, and Ryoichi Saito, and Koji Nishizawa, and Takashi Kobayashi, and Takahiro Inoue, and Shinya Oishi, and Nobutaka Fujii, and Jia-Jv Lv, and Osamu Ogawa, and Hiroyuki Nishiyama
January 2015, PloS one,
Nai-Dong Xing, and Sen-Tai Ding, and Ryoichi Saito, and Koji Nishizawa, and Takashi Kobayashi, and Takahiro Inoue, and Shinya Oishi, and Nobutaka Fujii, and Jia-Jv Lv, and Osamu Ogawa, and Hiroyuki Nishiyama
January 2008, Proteomics,
Nai-Dong Xing, and Sen-Tai Ding, and Ryoichi Saito, and Koji Nishizawa, and Takashi Kobayashi, and Takahiro Inoue, and Shinya Oishi, and Nobutaka Fujii, and Jia-Jv Lv, and Osamu Ogawa, and Hiroyuki Nishiyama
June 2010, Molecular cancer therapeutics,
Nai-Dong Xing, and Sen-Tai Ding, and Ryoichi Saito, and Koji Nishizawa, and Takashi Kobayashi, and Takahiro Inoue, and Shinya Oishi, and Nobutaka Fujii, and Jia-Jv Lv, and Osamu Ogawa, and Hiroyuki Nishiyama
April 2014, Journal of biochemistry,
Nai-Dong Xing, and Sen-Tai Ding, and Ryoichi Saito, and Koji Nishizawa, and Takashi Kobayashi, and Takahiro Inoue, and Shinya Oishi, and Nobutaka Fujii, and Jia-Jv Lv, and Osamu Ogawa, and Hiroyuki Nishiyama
October 2004, Biochemistry,
Nai-Dong Xing, and Sen-Tai Ding, and Ryoichi Saito, and Koji Nishizawa, and Takashi Kobayashi, and Takahiro Inoue, and Shinya Oishi, and Nobutaka Fujii, and Jia-Jv Lv, and Osamu Ogawa, and Hiroyuki Nishiyama
March 2002, Urological research,
Nai-Dong Xing, and Sen-Tai Ding, and Ryoichi Saito, and Koji Nishizawa, and Takashi Kobayashi, and Takahiro Inoue, and Shinya Oishi, and Nobutaka Fujii, and Jia-Jv Lv, and Osamu Ogawa, and Hiroyuki Nishiyama
June 2006, The Journal of biological chemistry,
Nai-Dong Xing, and Sen-Tai Ding, and Ryoichi Saito, and Koji Nishizawa, and Takashi Kobayashi, and Takahiro Inoue, and Shinya Oishi, and Nobutaka Fujii, and Jia-Jv Lv, and Osamu Ogawa, and Hiroyuki Nishiyama
January 1976, Journal of medicinal chemistry,
Copied contents to your clipboard!